<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940513-2-00110</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> June 13, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Public Health Service</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Final Notice Regarding Section 602 of the Veterans Health Care Act of 1992 Entity Guidelines</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Public Health Service, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=2 --> INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Section 602 of Public Law 102&hyph;585, the ``Veterans Health Care Act of 1992,'' enacted section 340B of the Public Health Service Act, ``Limitation on Prices of Drugs Purchased by Covered Entities.'' Section 340B provides that a manufacturer who sells covered outpatient drugs to eligible entities must agree to charge a price that will not exceed the amount determined under a statutory formula. The purpose of this notice is to inform interested parties of final program guidelines regarding eligible covered entities. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ACTION> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Marsha Alvarez, R.Ph., Director, Drug Pricing Program, Bureau of Primary Health Care, Health Resources and Services Administration, East West Towers rm 10&hyph;3A1, Bethesda, Maryland 20814, Phone: (301) 594&hyph;4353. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> June 13, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </DATE> <SUPPLEM> <!-- PJG ITAG l=84 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG 0012 frnewline --> (A) Background <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=2 --> Proposed entity guidelines were announced in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  at 58 FR 68922 on December 29, 1993. A comment period of 30 days was established to allow interested parties to submit comments. The Office of Drug Pricing received 7 letters with comments concerning confidential drug pricing information, retroactive discounts,drug diversion, audit requirements, entity participation, group purchasing, purchasing agents, manufacturer contracts, and 4 general comments. <!-- PJG 0012 frnewline --> The following section presents a summary of all major comments, grouped by subject, and a response to each comment. All comments were considered in developing this final notice. Changes were also made to increase clarity and readability. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> (B) Comments and Responses <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> Confidential Drug Pricing Information <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Establish specific sanctions for entities which knowingly make unauthorized disclosures. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  No change. The quoted price or the actual price given by the manufacturer to the covered entity is not confidential. Covered entities do not have access to confidential drug pricing information (i.e., average manufacturer price and best price). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> Eligibility for Retroactive Discounts <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Do not impose a deadline on requesting retroactive discounts. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  No change. It is a reasonable administrative decision to establish a time limit for requesting refunds. Manufacturers were given sufficient time in which to implement the discount program, and entities were given an adequate opportunity to elect whether to participate in the program. An entity may preserve its right to retroactive discounts, after the deadline, by sending each manufacturer a letter requesting such refunds and providing adequate documentation of drug purchases. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Exclude from eligibility for retroactive discounts any disproportionate share hospital (DSH) which purchased its outpatient drugs through a group purchasing organization (GPO). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  No change. The Office of Drug Pricing considers the outpatient drug purchases of DSHs bought through a GPO or any group purchasing arrangement ineligible for retroactive discounts. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Allow covered entities to request an extension of the deadline for retroactive discounts for good cause (e.g., offsite DSH clinics whose eligibility has not yet been determined). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  We have amended part 3 of the notice to permit a DSH outpatient clinic which was not participating in a GPO or any group purchasing arrangement during the period for which it is requesting retroactive discounts to preserve its right by sending manufacturers a letter requesting such refunds and providing adequate documentation of purchases. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Extend the deadline for those manufacturers which have refused to give PHS pricing to the date on which the manufacturer begins discounting its covered outpatient drugs in accordance with the law. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  No change. At every opportunity, the Office of Drug Pricing has communicated its willingness to assist entities with problems of accessing PHS pricing. It has responded to all entity complaints dealing with manufacturer noncompliance. We believe that one year is a reasonable time in which to have resolved any difficulty with pricing access. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Require manufacturers to respond within 30 days to requests for retroactive discounts, even if the response is just a request for additional information, or face possible termination from the Medicaid program. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  No change. Because this issue deals with manufacturer guidelines, it is beyond the scope of this notice. However, should a covered entity have difficulty obtaining retroactive discounts, we encourage the entity to contact the Office of Drug Pricing for assistance. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Establish that a DSH, which did not submit its Medicaid provider number for the period for which it is requesting retroactive discounts, would be ineligible for the refund. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  No change. A DSH which did not submit its Medicaid provider number may still be eligible for retroactive discounts if it (1) did not bill Medicaid for the drugs, (2) billed for covered outpatient drugs using an all-inclusive rate, or (3) has adequate documentation proving that drugs for which retroactive discounts are being requested did not generate Medicaid rebates. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> Drug Diversion <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment: <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Develop and publish a mechanism whereby manufacturers can report to the Office of Drug Pricing when they suspect an entity of diversion. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <!-- PJG /STAG --></p>
		</main>
</body></html>
            